0.06
+0.0084(+16.28%)
Currency In USD
| Previous Close | 0.05 |
| Open | 0.05 |
| Day High | 0.06 |
| Day Low | 0.05 |
| 52-Week High | 21 |
| 52-Week Low | 0.04 |
| Volume | 92,282 |
| Average Volume | 322,306 |
| Market Cap | 2.02M |
| PE | 0 |
| EPS | 323.08 |
| Moving Average 50 Days | 0.09 |
| Moving Average 200 Days | 0.79 |
| Change | 0.01 |
If you invested $1000 in Windtree Therapeutics, Inc. (WINT) 10 years ago, it would be worth $0 as of December 04, 2025 at a share price of $0.062. Whereas If you bought $1000 worth of Windtree Therapeutics, Inc. (WINT) shares 5 years ago, it would be worth $0 as of December 04, 2025 at a share price of $0.062.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space
GlobeNewswire Inc.
Yesterday at 2:00 PM GMT
Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans are originated CommLoan has streamlined the proc
Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee
GlobeNewswire Inc.
Nov 17, 2025 2:00 PM GMT
The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed treatments include SURFAXIN®, lyophilized lucinact
Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate
GlobeNewswire Inc.
Nov 14, 2025 2:00 PM GMT
Windtree has a total of 59 issued or allowed patents and 17 pending patents for Istaroxime and its SERCA2a activators Windtree received recent notification of allowed Istaroxime patents for acute heart failure in Canada and Mexico The pure SERCA2a ac